Population characteristics
| . | Training cohort (n = 10 016) . | Validation cohort (n = 1802) . | Total cohort . |
|---|---|---|---|
| n (%) . | n (%) . | n (%) . | |
| Recipient age, y | |||
| 0-19 | 1159 (11.6%) | 179 (9.9%) | 1338 (11.3%) |
| 20-39 | 1470 (14.7%) | 255 (14.2%) | 1725 (14.6%) |
| 40-59 | 3167 (31.6%) | 537 (29.8%) | 3704 (31.3%) |
| 60-82 | 4220 (42.1%) | 831 (46.1%) | 5051 (42.7%) |
| Recipient sex, male | 5828 (58.2%) | 1059 (58.8%) | 6887 (58.3%) |
| Recipient race | |||
| White | 8993 (93.0%) | 1619 (92.8%) | 10612 (93.0%) |
| Black | 307 (3.2%) | 57 (3.3%) | 364 (3.2%) |
| Asian | 281 (2.9%) | 56 (3.2%) | 337 (3.0%) |
| Other | 86 (0.9%) | 13 (0.7%) | 99 (0.9%) |
| Missing | 349 | 57 | 406 |
| Recipient ethnicity | |||
| Hispanic | 764 (7.9%) | 143 (8.3%) | 907 (8.0%) |
| Missing | 359 | 81 | 440 |
| Donor age, y | |||
| 18-29 | 6499 (65.4%) | 1176 (65.7%) | 7675 (65.4%) |
| 30-39 | 2291 (23.0%) | 411 (22.9%) | 2702 (23.0%) |
| 40-49 | 855 (8.6%) | 148 (8.3%) | 1003 (8.5%) |
| 50-60 | 296 (3.0%) | 56 (3.1%) | 352 (3.0%) |
| Missing | 75 | 11 | 86 |
| Donor parity | |||
| Male | 6985 (70.2%) | 1245 (69.4%) | 8230 (70.0%) |
| Female-nulliparous | 1886 (18.9%) | 370 (20.6%) | 2256 (19.2%) |
| Female-parous | 1086 (10.9%) | 179 (10.0%) | 1265 (10.8%) |
| Missing | 59 | 8 | 67 |
| Sex matching, recipient/donor | |||
| Male/male | 4287 (43.1%) | 769 (42.9%) | 5056 (43.0%) |
| Male/female | 1508 (15.1%) | 286 (15.9%) | 1794 (15.3%) |
| Female/male | 2698 (27.1%) | 476 (26.5%) | 3174 (27.0%) |
| Female/female | 1464 (14.7%) | 263 (14.7%) | 1727 (14.7%) |
| Missing | 59 | 8 | 67 |
| CMV serostatus (recipient/donor) | |||
| −/− | 2783 (27.9%) | 503 (28.2%) | 3286 (28.0%) |
| −/+ | 1162 (11.7%) | 205 (11.5%) | 1367 (11.6%) |
| +/− | 3240 (32.5%) | 591 (33.1%) | 3831 (32.6%) |
| +/+ | 2777 (27.9%) | 487 (27.3%) | 3264 (27.8%) |
| Missing | 54 | 16 | 70 |
| DQB1 match | |||
| Yes | 9377 (95.6%) | 1699 (95.8%) | 11076 (95.6%) |
| Missing | 206 | 29 | 235 |
| DPB1 match or permissive mismatch | |||
| Yes | 6430 (75.4%) | 1171 (76.3%) | 7601 (75.5%) |
| Missing | 1490 | 267 | 1757 |
| Graft type | |||
| Bone marrow | 2239 (22.4%) | 384 (21.3%) | 2623 (22.2%) |
| Peripheral blood | 7777 (77.6%) | 1418 (78.7%) | 9195 (77.8%) |
| Karnofsky score | |||
| ≤60 | 144 (1.5%) | 25 (1.4%) | 169 (1.5%) |
| 70 | 1268 (12.9%) | 222 (12.6%) | 1490 (12.9%) |
| 80 | 2896 (29.5%) | 557 (31.6%) | 3453 (29.8%) |
| 90 | 3971 (40.5%) | 701 (39.7%) | 4672 (40.4%) |
| 100 | 1528 (15.6%) | 259 (14.7%) | 1787 (15.4%) |
| Missing | 209 | 38 | 247 |
| Disease∗ | |||
| ALL | 1290 (12.9%) | 251 (13.9%) | 1541 (13.0%) |
| AML | 3956 (39.5%) | 746 (41.4%) | 4702 (39.8%) |
| CLL | 139 (1.4%) | 26 (1.4%) | 165 (1.4%) |
| CML | 269 (2.7%) | 47 (2.6%) | 316 (2.7%) |
| MDS | 1988 (19.8%) | 362 (20.1%) | 2350 (19.9%) |
| MM | 128 (1.3%) | 26 (1.4%) | 154 (1.3%) |
| NHL | 617 (6.2%) | 94 (5.2%) | 711 (6.0%) |
| Other | 1629 (16.3%) | 250 (13.9%) | 1879 (15.9%) |
| Disease stage (ALL, AML, MDS only) | 6947 | 1306 | 8253 |
| Early | 4159 (59.9%) | 775 (59.3%) | 4934 (59.8%) |
| Intermediate | 1360 (19.6%) | 261 (20.0%) | 1621 (19.6%) |
| Advanced | 1428 (20.6%) | 270 (20.7%) | 1698 (20.6%) |
| Missing | 287 | 53 | 340 |
| Conditioning regimen | |||
| Myeloablative | 4974 (49.7%) | 885 (49.1%) | 5859 (49.6%) |
| Nonmyeloablative | 1122 (11.2%) | 213 (11.8%) | 1335 (11.3%) |
| Reduced intensity | 3920 (39.1%) | 704 (39.1%) | 4624 (39.1%) |
| GVHD prophylaxis | |||
| PTCy | 1130 (11.3%) | 216 (12.0%) | 1346 (11.4%) |
| Tac + MMF | 1097 (11.0%) | 209 (11.6%) | 1306 (11.1%) |
| Tac + MTX | 5425 (54.2%) | 965 (53.6%) | 6390 (54.1%) |
| Tac only | 1020 (10.2%) | 196 (10.9%) | 1216 (10.3%) |
| CSA + MMF | 430 (4.3%) | 84 (4.7%) | 514 (4.3%) |
| CSA + MTX | 356 (3.6%) | 61 (3.4%) | 417 (3.5%) |
| CSA only | 65 (0.6%) | 14 (0.8%) | 79 (0.7%) |
| Other | 493 (4.9%) | 57 (3.2%) | 550 (4.7%) |
| HCT-comorbidity index | |||
| 0 | 2093 (21.1%) | 333 (18.7%) | 2426 (20.7%) |
| 1-2 | 2938 (29.6%) | 547 (30.6%) | 3485 (29.7%) |
| 3-4 | 3050 (30.7%) | 539 (30.2%) | 3589 (30.6%) |
| 5+ | 1851 (18.6%) | 366 (20.5%) | 2217 (18.9%) |
| Missing | 84 | 17 | 101 |
| Time from diagnosis to HCT | |||
| 0-6 mo | 4311 (43.11%) | 754 (42.0%) | 5065 (43%) |
| >6-12 mo | 2511 (25.1%) | 475 (26.4%) | 2986 (25.3%) |
| >12-18 mo | 785 (7.9%) | 151 (8.4%) | 936 (7.9%) |
| >18-24 mo | 457 (4.6%) | 89 (5.0%) | 546 (4.6%) |
| >24 mo | 1931 (19.3%) | 327 (18.2%) | 2258 (19.2%) |
| Missing | 21 | 6 | 27 |
| Transplant year | |||
| 2016 | 2347 (23.4%) | 419 (23.3%) | 2766 (23.4%) |
| 2017 | 2527 (25.2%) | 438 (24.3%) | 2965 (25.1%) |
| 2018 | 2593 (25.9%) | 450 (25.0%) | 3043 (25.7%) |
| 2019 | 2549 (25.4%) | 495 (27.5%) | 3044 (25.8%) |
| . | Training cohort (n = 10 016) . | Validation cohort (n = 1802) . | Total cohort . |
|---|---|---|---|
| n (%) . | n (%) . | n (%) . | |
| Recipient age, y | |||
| 0-19 | 1159 (11.6%) | 179 (9.9%) | 1338 (11.3%) |
| 20-39 | 1470 (14.7%) | 255 (14.2%) | 1725 (14.6%) |
| 40-59 | 3167 (31.6%) | 537 (29.8%) | 3704 (31.3%) |
| 60-82 | 4220 (42.1%) | 831 (46.1%) | 5051 (42.7%) |
| Recipient sex, male | 5828 (58.2%) | 1059 (58.8%) | 6887 (58.3%) |
| Recipient race | |||
| White | 8993 (93.0%) | 1619 (92.8%) | 10612 (93.0%) |
| Black | 307 (3.2%) | 57 (3.3%) | 364 (3.2%) |
| Asian | 281 (2.9%) | 56 (3.2%) | 337 (3.0%) |
| Other | 86 (0.9%) | 13 (0.7%) | 99 (0.9%) |
| Missing | 349 | 57 | 406 |
| Recipient ethnicity | |||
| Hispanic | 764 (7.9%) | 143 (8.3%) | 907 (8.0%) |
| Missing | 359 | 81 | 440 |
| Donor age, y | |||
| 18-29 | 6499 (65.4%) | 1176 (65.7%) | 7675 (65.4%) |
| 30-39 | 2291 (23.0%) | 411 (22.9%) | 2702 (23.0%) |
| 40-49 | 855 (8.6%) | 148 (8.3%) | 1003 (8.5%) |
| 50-60 | 296 (3.0%) | 56 (3.1%) | 352 (3.0%) |
| Missing | 75 | 11 | 86 |
| Donor parity | |||
| Male | 6985 (70.2%) | 1245 (69.4%) | 8230 (70.0%) |
| Female-nulliparous | 1886 (18.9%) | 370 (20.6%) | 2256 (19.2%) |
| Female-parous | 1086 (10.9%) | 179 (10.0%) | 1265 (10.8%) |
| Missing | 59 | 8 | 67 |
| Sex matching, recipient/donor | |||
| Male/male | 4287 (43.1%) | 769 (42.9%) | 5056 (43.0%) |
| Male/female | 1508 (15.1%) | 286 (15.9%) | 1794 (15.3%) |
| Female/male | 2698 (27.1%) | 476 (26.5%) | 3174 (27.0%) |
| Female/female | 1464 (14.7%) | 263 (14.7%) | 1727 (14.7%) |
| Missing | 59 | 8 | 67 |
| CMV serostatus (recipient/donor) | |||
| −/− | 2783 (27.9%) | 503 (28.2%) | 3286 (28.0%) |
| −/+ | 1162 (11.7%) | 205 (11.5%) | 1367 (11.6%) |
| +/− | 3240 (32.5%) | 591 (33.1%) | 3831 (32.6%) |
| +/+ | 2777 (27.9%) | 487 (27.3%) | 3264 (27.8%) |
| Missing | 54 | 16 | 70 |
| DQB1 match | |||
| Yes | 9377 (95.6%) | 1699 (95.8%) | 11076 (95.6%) |
| Missing | 206 | 29 | 235 |
| DPB1 match or permissive mismatch | |||
| Yes | 6430 (75.4%) | 1171 (76.3%) | 7601 (75.5%) |
| Missing | 1490 | 267 | 1757 |
| Graft type | |||
| Bone marrow | 2239 (22.4%) | 384 (21.3%) | 2623 (22.2%) |
| Peripheral blood | 7777 (77.6%) | 1418 (78.7%) | 9195 (77.8%) |
| Karnofsky score | |||
| ≤60 | 144 (1.5%) | 25 (1.4%) | 169 (1.5%) |
| 70 | 1268 (12.9%) | 222 (12.6%) | 1490 (12.9%) |
| 80 | 2896 (29.5%) | 557 (31.6%) | 3453 (29.8%) |
| 90 | 3971 (40.5%) | 701 (39.7%) | 4672 (40.4%) |
| 100 | 1528 (15.6%) | 259 (14.7%) | 1787 (15.4%) |
| Missing | 209 | 38 | 247 |
| Disease∗ | |||
| ALL | 1290 (12.9%) | 251 (13.9%) | 1541 (13.0%) |
| AML | 3956 (39.5%) | 746 (41.4%) | 4702 (39.8%) |
| CLL | 139 (1.4%) | 26 (1.4%) | 165 (1.4%) |
| CML | 269 (2.7%) | 47 (2.6%) | 316 (2.7%) |
| MDS | 1988 (19.8%) | 362 (20.1%) | 2350 (19.9%) |
| MM | 128 (1.3%) | 26 (1.4%) | 154 (1.3%) |
| NHL | 617 (6.2%) | 94 (5.2%) | 711 (6.0%) |
| Other | 1629 (16.3%) | 250 (13.9%) | 1879 (15.9%) |
| Disease stage (ALL, AML, MDS only) | 6947 | 1306 | 8253 |
| Early | 4159 (59.9%) | 775 (59.3%) | 4934 (59.8%) |
| Intermediate | 1360 (19.6%) | 261 (20.0%) | 1621 (19.6%) |
| Advanced | 1428 (20.6%) | 270 (20.7%) | 1698 (20.6%) |
| Missing | 287 | 53 | 340 |
| Conditioning regimen | |||
| Myeloablative | 4974 (49.7%) | 885 (49.1%) | 5859 (49.6%) |
| Nonmyeloablative | 1122 (11.2%) | 213 (11.8%) | 1335 (11.3%) |
| Reduced intensity | 3920 (39.1%) | 704 (39.1%) | 4624 (39.1%) |
| GVHD prophylaxis | |||
| PTCy | 1130 (11.3%) | 216 (12.0%) | 1346 (11.4%) |
| Tac + MMF | 1097 (11.0%) | 209 (11.6%) | 1306 (11.1%) |
| Tac + MTX | 5425 (54.2%) | 965 (53.6%) | 6390 (54.1%) |
| Tac only | 1020 (10.2%) | 196 (10.9%) | 1216 (10.3%) |
| CSA + MMF | 430 (4.3%) | 84 (4.7%) | 514 (4.3%) |
| CSA + MTX | 356 (3.6%) | 61 (3.4%) | 417 (3.5%) |
| CSA only | 65 (0.6%) | 14 (0.8%) | 79 (0.7%) |
| Other | 493 (4.9%) | 57 (3.2%) | 550 (4.7%) |
| HCT-comorbidity index | |||
| 0 | 2093 (21.1%) | 333 (18.7%) | 2426 (20.7%) |
| 1-2 | 2938 (29.6%) | 547 (30.6%) | 3485 (29.7%) |
| 3-4 | 3050 (30.7%) | 539 (30.2%) | 3589 (30.6%) |
| 5+ | 1851 (18.6%) | 366 (20.5%) | 2217 (18.9%) |
| Missing | 84 | 17 | 101 |
| Time from diagnosis to HCT | |||
| 0-6 mo | 4311 (43.11%) | 754 (42.0%) | 5065 (43%) |
| >6-12 mo | 2511 (25.1%) | 475 (26.4%) | 2986 (25.3%) |
| >12-18 mo | 785 (7.9%) | 151 (8.4%) | 936 (7.9%) |
| >18-24 mo | 457 (4.6%) | 89 (5.0%) | 546 (4.6%) |
| >24 mo | 1931 (19.3%) | 327 (18.2%) | 2258 (19.2%) |
| Missing | 21 | 6 | 27 |
| Transplant year | |||
| 2016 | 2347 (23.4%) | 419 (23.3%) | 2766 (23.4%) |
| 2017 | 2527 (25.2%) | 438 (24.3%) | 2965 (25.1%) |
| 2018 | 2593 (25.9%) | 450 (25.0%) | 3043 (25.7%) |
| 2019 | 2549 (25.4%) | 495 (27.5%) | 3044 (25.8%) |
CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.
Other diseases included inherited erythrocyte abnormalities, inherited immune syndrome, severe aplastic anemia, and other nonmalignant conditions.